De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line

Anticancer Research

Volumn 19, Issue 6 B, 1999, Pages 5131-5137

  Asada, Naohiro ^a   Tsuchiya, Hiroyuki ^a   Tomita, Katsuro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cisplatin; Drug resistance; Osteosarcoma; Tumor suppressor gene

Indexed keywords

ANTIBODY; CISPLATIN; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CHROMOSOME 17; CHROMOSOME 17P; CONTROLLED STUDY; DELETION MUTANT; DRUG RESISTANCE; ENZYME IMMUNOASSAY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC STABILITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OSTEOSARCOMA; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 17; CISPLATIN; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; OSTEOSARCOMA; TUMOR CELLS, CULTURED;

EID: 0033368192     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Isobe M, Emanuel BS, Givol D, Oren M, and Croce CM: Localization of gene for human p53 tumor antigen to band 17p13. Nature 320: 84-85, 1986.
2. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fucks R, Sorlie T, Hoving E, Smith-Sorensen B, Montesano R, and Harris CC: Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22: 3551-3555, 1994.
3. Miller CW, Also A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, and Koeffler HP: Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 50: 7950-7954, 1990.
4. Toguchida J, Ishizaki K, Nakamura Y, Sasaki MS, Ikenaga M, Kato M, Sugimoto M, Kotoura Y, and Yamamuro T: Assignment of common allele loss in osteosarcoma to the subregion 17p13. Cancer Res 49: 6247-6251, 1989.
5. Mulligan LM, Matlashewski GJ, Scrable HJ, and Cavenee WK: Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA 87: 5863-5867, 1990.
6. Yamaguchi T, Toguchida J, Yamamuro T, Kotoura Y, Takada N, Kawaguchi N, Kaneko Y, Nakamura Y, Sasaki MS, and Isizaki K: Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q,17p, and 18q. Cancer Res 52: 2419-2423, 1992.
7. Lonard F, Ueda T, Huvos AG, Healey J, and Ladanyi M: p53 and MDM2 alternations in osteosarcomas. Cancer 79: 1541-1547, 1997.
8. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, and Friend SH: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10: 5772-5781, 1990.
9. Kastan MB, Onyerkwere O, Sidransky D, Vogelstein B, and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 53: 6304-6311, 1991.
10. Lowe SW, Ruley HE, Jacks T, and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
11. Hawkins DS, Demers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898, 1996.
12. Wahl AF, Donaldson KL, Frairchild C, Lee FYF, Foster SA, Demers GW, and Galloway DA: Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72-79, 1996.
13. Wu GS, and El-Deiry WS: p53 and chemosensitivity. Nat Med 2: 255-256, 1996.
14. Wu GS, and El-Deiry WS: Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 and Bcl-2. Clin Cancer Res 2: 623-633, 1996.
15. Russell KJ, Wiens LW, Demers GW, Galloway DA, Plon SE, and Groudline M: Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res 55: 1639-1642, 1995.
16. Fan S, Smith ML, Rivet II DJ, Duba D, Zahn Q, Kohn KW, Fornance AJ Jr, and O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
17. Lowe SW, Bois S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
18. Gallardo D, Drazan KE, and McBride WH: Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res 56: 4891-4893, 1996.
19. Siles E, Villalobos M, Valenzuela MT, Nunez MI, Gordon A, McMillan TJ, Pedraza, V, and Ruiz de Almodovar JM: Relationship between p53 status and radiosensitivity in human tumor cell lines. Br J Cancer 73: 581-585, 1996.
20. Delia D, Mizutani S, Lamorte G, Goi K, Iwata S, and Pierotti MA: p53 activity and chemotherapy. Nat Med 2: 724-725, 1996.
21. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, and Dmitrovsky E: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55: 5038-5042, 1995.
22. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, and Lonning PE: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-814.
23. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, and Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562, 1996.
24. Tsuchiya H, Morishita H, Tomita K, Ueda Y, and Tanaka M: Differentiating and antitumor activities of 1 alpha-hydroxyvitamin D3 in vitro on human osteosarcoma. J. Orthop Res 11: 122-130, 1993.
25. Asada N, Tsuchiya H, Ueda Y, and Tomita K. Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line. Anticancer Res 18 (3A): 1765-1768, 1998.
26. Kobayashi M, Kawashima A, Mai M, and Ooi A: Analysis of chromosome 17p13(p53 locus) alternations in gastric carcinoma cells by dual color fluorescence in situ hybridization. Am J Pathol 149: 1574-1584, 1996.
27. Matsumura K, Kallioniemi A, Kallioniemi O, Chen L, Smith HS, Pinkel D, Gray J, and Waldman FM: Deletion of chromosome 17p loci in breast cancer detected by fluorescence in situ hybridization. Cancer Res 52: 3474-3477, 1992.
28. Sauter G, Deng G, Moch H, Kerschmann R, Mastumura K, De Vries S, George T, Fuentes J, Carroll P, Mihatsch MJ, and Waldman FM: Physical deletion of the p53 gene in bladder cancer: Detection by fluorescence in situ hybridization. Am J Pathol 144: 756-766, 1994.
29. Ishino Y, Mineno J, Inoue T, Fujimiya H, Yamamoto K, Tamura T, Honma M, Tanaka K, and Kato I: Practical applications in molecular biology of sensitive fluorescence detection by a laser-excited fluorescence image analyzer. BioTechniques 13: 936-943, 1992.
30. Gomyo Y, Osaki M, Kaibara N, and Ito H: Numerical aberration and point mutation of p53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR-SSCP. Int J Cancer 66: 594-599, 1996.
31. Takahashi-Fujii A, Ishino Y, Shimada A, and Kato I: Practical application of fluorescence-based image analyzer for PCR single-stranded conformation polymorphism analysis used in detection of multiple point mutations. PCR Methods Applic 2: 323-327, 1993.
32. Zheng W-P, and Nakamura I: Multiplex PCR-SSCP for simultaneous screening for mutations in several exons of p53. BioTechniques 18: 742-744, 1995.
33. Romano JW, Ehrhart JC, Duths A, Kim CM, Appella E, and May P: Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line. Oncogene 4: 1438-1488, 1989.
34. Jaffe N, Knapp J, Chuang VP, Wallace S, Ayala A, Murray J, Cangir A, Wand A, and Benjamin RS: Osteosarcoma: Intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, pharmacologic studies. Cancer 51: 402-407, 1983.
35. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB, Weichselbaum RR, Ishizaki K, and Yandell DW: Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52: 6194-6199, 1992.
36. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, and Tisty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935, 1992.
37. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, and Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937-948, 1992.
38. Agapova LS, Ilyinskaya GV, Turovets NA, Ivarov AV, Chumakov PM, and Kopnin, BP: Chromosome changes caused by alternations of p53 expression. Mutation Res 354: 129-138, 1996.
39. Maass JD, Gottschlich S, Goerorgh T, Bruhn T, Lippert BM, Paulsen JP, and Werner JA: High rate of p53 overexpression in head and neck carcinomas detected with a refined ELISA. Anticancer Res 17: 473-478, 1997.
40. Vojtesek B, Fischer CJ, Barnes DM and Lane DP: Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br J Cancer 67: 1254-1258, 1993.
41. Chen X, Ko LJ, Jayaraman L and Prives C: p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes and Dev 10: 2438-2451, 1996.